Stay updated with breaking news from Nasdaq Edit. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Shares of Editas Medicine, Inc. (NASDAQ:EDIT – Get Free Report) have earned an average recommendation of “Moderate Buy” from the nine brokerages that are presently covering the company, MarketBeat Ratings reports. Four analysts have rated the stock with a hold recommendation and five have assigned a buy recommendation to the company. The average 1-year price […]
Shares of Editas Medicine, Inc. (NASDAQ:EDIT – Get Free Report) have received a consensus rating of “Moderate Buy” from the nine analysts that are currently covering the stock, Marketbeat reports. Four research analysts have rated the stock with a hold recommendation and five have assigned a buy recommendation to the company. The average 12 month […]
Editas Medicine, Inc. (NASDAQ:EDIT – Free Report) – Analysts at Zacks Research increased their Q1 2024 EPS estimates for shares of Editas Medicine in a research note issued on Thursday, February 15th. Zacks Research analyst A. Chakraborty now expects that the company will earn ($0.71) per share for the quarter, up from their prior estimate […]
Raymond James & Associates lifted its stake in Editas Medicine, Inc. (NASDAQ:EDIT – Free Report) by 5.8% in the 3rd quarter, Holdings Channel reports. The institutional investor owned 274,303 shares of the company’s stock after acquiring an additional 14,994 shares during the period. Raymond James & Associates’ holdings in Editas Medicine were worth $2,140,000 as […]
Editas Medicine, Inc. (NASDAQ:EDIT – Get Free Report) saw a significant decrease in short interest in December. As of December 31st, there was short interest totalling 12,790,000 shares, a decrease of 14.6% from the December 15th total of 14,970,000 shares. Based on an average daily volume of 1,840,000 shares, the days-to-cover ratio is presently 7.0 […]